ENDOVASCULAR OCCLUSION OF THE PATENT FORAMEN OVALE AS PART OF ANTIARRHYTHMIC TREATMENT OF A PATIENT WITH PERSISTENT ATRIAL FIBRILLATION (CASE REPORT)

Below is a case report of treatment of a patient with persistent tachysystolic atrial fibrillation (AF), chronic heart failure (CHF) with a moderately reduced left ventricular ejection fraction (EF) and patent foramen ovale (PFO) with an atrial septal aneurysm. A 58-year-old man (with body mass index of 27.8 kg/m2) with tachysystolic persistent AF (duration 3 months) was hospitalized due to an increase in CHF symptoms (CHF functional class according to NYHA is II-III). The patient had been constantly receiving therapy in accordance with current recommendations (angiotensin receptor blockers, diuretics, beta-blockers, amiodorone and rivaroxaban). Transthoracic echocardiography showed a moderate decrease in ejection fraction (EF) (41%), an increase in the left (47 mm) and right (51x74 mm) atria. The patient underwent AF radiofrequency catheter ablation (RFA) in the left atrium, which identified PFO. The final stage of RFA was performed by external electrical cardioversion with successful restoration of sinus rhythm. Four months after RFA, despite a stable sinus rhythm, the patient maintained a moderately reduced LV EF (44%) and dilatation of the left (44 mm) and right (43x65 mm) atria. Transesophageal echocardiography revealed an aneurysmally altered atrial septum and a positive bubble test with a large number of bubbles. In accordance with current recommendations, the patient had indications for primary prevention of stroke - endovascular occlusion of the PFO, which was performed. Three months after PFO closure, the patient discontinued diuretics, amiodarone, and rivaroxaban. Combined therapy in a patient with persistent AF, with a moderately reduced EF and verified PFO, which included pathogenetic therapy for CHF, prescription of antiarrhythmic drugs, RFA of the AF substrate, and interventional closure of the PFO, made it possible to effectively control sinus rhythm, significantly reduce the manifestations of CHF and provide primary prevention of embolic disorders

Mathematical modelling of the railway station’s technological parameters in transport corridor system of export traffic increasing volumes

The study substantiates the need to develop mathematical analysis methods of railway station technology in the context of increasing the volume of freight traffic through the constituent elements of the infrastructure of the international transport corridor. The aim of the work is to develop proposals for improving the station operation technology under the conditions of its additional functions, to analyse the unevenness of the station transportation process and to assess changes in the transport corridor parameters. The object of the study is the Astrakhan-II station of the Volga Railway (JSC "Russian Railways"), located within the boundaries of the international corridor "North-South". In the article on the example of a particular station, its technical and operational characteristics, time norms for the performance of various technological operations, the unevenness of the station process is assessed, and a mathematical model of the station operation as a mass service system is developed. The "bottlenecks" are identified and proposals are formed to increase the processing capacity of the station, aimed at reducing channel utilisation and downtime duration. The results of the mathematical model are supplemented with technological proposals to change the formation plan of the Astrakhan II station to assist the port of Olya in picking up ship consignments in order to maximise the efficient use of Astrakhan II station capacity and reduce the need for track development in the port of Olya for marshalling operations, and consequently reduce the cost of its development. As part of compliance with the coordinated development of all elements of transport infrastructure, the capacity of the railway approaches to the station is assessed and a final set of measures is established

Production of biomedical cell products: Requirements for the quality of donor material and excipients of animal origin (review)

Donor biological materials and excipients of animal origin are important components in the production of biomedical cell products (BMCPs). Their quality ensures the stability, safety, effectiveness and purity of the final product. This review discusses quality requirements for biological excipients intended for the production of biomedical cell products, in terms of the necessary information that should be included in the BMCP registration dossier during state registration and is subject to expert assessment during quality control. Considering that there is currently no production of biomedical cell products in the Russian Federation, the authors considered international approaches to ensuring the safety of donor material and excipients for the manufacturing of human cell- and tissue-based products (BMCP analogues). This journal is © The Royal Society of Chemistry

Номенклатура генотерапевтических лекарственных препаратов: международный опыт

The development of innovative gene therapy drugs for «personalized» therapy is becoming a megatrend of Biomedicine and the global biopharmaceutical market. Due to the question of the creation of the national nomenclature of these drugs is essential one. The article attempts to summarize the existing international experience in the development of the nomenclature of drug products for gene therapy, as well as to formulate national approaches to the nomenclature of drug products for gene therapy. The analysis shows the feasibility of harmonization of the national nomenclature of gene therapy drugs with the system of international nonproprietary names developed by WHO.Разработка инновационных генотерапевтических лекарственных препаратов для персонализированной терапии становится мегатрендом развития биомедицины и мирового биофармацевтического рынка. В связи с этим актуален вопрос о формировании национальной номенклатуры этих препаратов. В статье сделана попытка обобщить имеющийся международный опыт. Проведенный анализ свидетельствует о целесообразности гармонизации национальной номенклатуры генотерапевтических лекарственных препаратов с системой международных непатентованных наименований, разработанной ВОЗ